Erdafitinib is the only FGFRi approved for bladder cancer harboring any of only four point mutations in the FGFR3 extracellular domain (Arg248Cys, Ser249Cys, Gly370Cys and Tyr373Cys). Here, FGFR3 is linked to urinary bladder carcinoma.